Patent · US Active

Primary cell gene editing

US10711283B2 · kind B2 · utility

0Cited by
5References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 5, 2020
Grant dateJul 14, 2020
Priority date—
Expiry dateFeb 5, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16043
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.